Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREDIT-5: IBI306 in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
NCT07473960Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in hypercholesterolemia, mixed hyperlipidemia, sponsored by Innovent Biologics. Started Apr 2026; status: active, not recruiting.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT07473960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473960.